|View printer-friendly version|
|Incyte Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disease Day 2017|
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170228005457/en/
“Raising awareness and educating the global community about rare
diseases is critical to helping improve the lives of patients and
families affected by these conditions,” said Hervé Hoppenot, CEO of
MPNs are chronic, progressive blood cancers that can strike anyone at any age. MPNs occur when the bone marrow cells that produce the body's blood cells develop and function abnormally. The three main MPNs are myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET).
This year, as part of its ongoing MPN educational efforts,
Rare Disease Day is an important time to recognize and honor the patients, doctors, caregivers, advocates and organizations that contribute to bringing understanding, compassion and strength to those living with rare disease like MPNs. The MPN Heroes Recognition Program, now in its fifth year, is sponsored by Incyte in collaboration with CURE Media Group, publishers of CURE® magazine. The MPN Heroes® program recognizes individuals and organizations who have contributed to the MPN community by going above and beyond to make a real difference. Nominations for the 2017 MPN Heroes program will be accepted online, by mail or by phone beginning on Rare Disease Day through September, 14, 2017. To learn more about the program or to submit a nomination, visit http://www.mpnheroes.com for more details.
On Rare Disease Day, MPN patients, physicians and caregivers are also
encouraged to share their stories, show their support and help raise
awareness of these rare disorders via the Voices
of MPN website and
About Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPNs) are a closely related group of blood cancers in which the bone marrow cells that produce the body’s blood cells develop and function abnormally.1 The three main myeloproliferative neoplasms are myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET).1 MPNs are progressive blood cancers that can strike anyone at any age, but they are more common in older adults. Estimates of the prevalence of MPNs vary, but analysis of claims data suggests there may be as many as 200,000 people in the U.S. living with MF, PV or ET.2
MPN Heroes and Voices of MPN are registered trademarks of